Get a glimpse into our company and investor data—powered by the PitchBook Platform
M&ALATEST DEAL TYPE
$1.7BLATEST DEAL AMOUNT
Developer of antiviral compounds for treating human immunodeficiency virus (HIV) infection. The company develops TBR-652 and TBR-220 antagonists for the treatment of HIV or AIDS, hepatitis and related infectious conditions.